Today: 8 February 2026
Subscribe

EQT slides as U.S. natural gas futures sink on LNG feedgas drop

EQT slides as U.S. natural gas futures sink on LNG feedgas drop

EQT shares fell about 3% to $50.03 Wednesday after U.S. natural gas futures slid 6.7% to $3.189/mmBtu, pressured by reduced LNG feedgas flows in Texas. Antero and Range also declined, while Coterra edged higher. Waha Hub cash prices in West Texas stayed below zero due to pipeline bottlenecks. Traders await Thursday’s U.S. storage report as colder weather is forecast next week.
14 January 2026
·······
Bitcoin price jumps near $97,000 as Senate crypto bill and Fed rate bets lift Coinbase, Strategy stocks

Bitcoin price jumps near $97,000 as Senate crypto bill and Fed rate bets lift Coinbase, Strategy stocks

Bitcoin rose 3.5% to $96,839 Wednesday, lifting U.S.-listed crypto stocks in New York trading. U.S. inflation data showed CPI up 0.3% in December and 2.7% year over year. Senators introduced draft legislation on crypto regulation as spot bitcoin ETFs saw $753.8 million in net inflows Tuesday. U.S. stocks dipped and Treasury yields slipped after retail sales and producer price data.
14 January 2026
·····
Infosys stock jumps nearly 9% after INFY lifts FY26 outlook — what investors watch next

Infosys stock jumps nearly 9% after INFY lifts FY26 outlook — what investors watch next

Infosys’ U.S. shares jumped 8.9% to $19.08 after the company raised its fiscal 2026 revenue growth outlook to 3.0%-3.5% and reported $5.099 billion in quarterly revenue. Net profit in India fell 2.2% due to a one-time charge. Large deal wins totaled $4.8 billion. Bank of America raised its price target to $20.50, citing stronger growth in key sectors.
14 January 2026
··
Gold price today: record above $4,600 lifts GLD stock as Fed cut bets grow

Gold price today: record above $4,600 lifts GLD stock as Fed cut bets grow

Spot gold hit a record $4,641.40 an ounce Wednesday, with silver also reaching a new high at $92.23, as traders bet on U.S. rate cuts after inflation data. The core Consumer Price Index rose 0.2% in December and 2.6% year-over-year. Retail sales and producer prices both rose more than expected. The Federal Reserve is expected to hold rates steady at its Jan. 27-28 meeting.
14 January 2026
······
Terns Pharmaceuticals stock jumps 10% as JPM conference puts TERN-701 back on the map

Terns Pharmaceuticals stock jumps 10% as JPM conference puts TERN-701 back on the map

Terns Pharmaceuticals shares rose 10.4% to $38.03 by midday Wednesday after the company announced 2026 targets for its chronic myeloid leukemia drug at the JPMorgan Healthcare Conference. The company plans a pivotal dose selection and an FDA meeting by mid-2026, following early trial data showing a 75% major molecular response at 24 weeks. Investors are watching for longer-term results and regulatory milestones.
14 January 2026
··
CompoSecure stock jumps on $2.5 billion refinancing, GPGI ticker switch ahead

CompoSecure stock jumps on $2.5 billion refinancing, GPGI ticker switch ahead

CompoSecure shares rose about 8% Wednesday after the company announced a $900 million private placement of senior secured notes due 2033 with a 5.625% coupon and a $1.2 billion term loan. The company also confirmed its acquisition of Husky Technologies and will rebrand, trading as “GPGI” from Jan. 23. The Husky deal included $688.7 million in cash and nearly 55 million Class A shares.
14 January 2026
·
Cogent Biosciences (COGT) stock jumps as FDA filing timeline sharpens — what investors watch next

Cogent Biosciences (COGT) stock jumps as FDA filing timeline sharpens — what investors watch next

Cogent Biosciences shares climbed about 8% Wednesday after the company set a 2026 timetable for U.S. filings of its lead drug, bezuclastinib. Cogent expects FDA acceptance of its first application by the end of February and aims for a possible commercial launch in the second half of 2026. The stock traded at $38.17 midday. The company began the year with about $900 million in cash.
14 January 2026
·
Viking Therapeutics stock jumps 11% as CEO flags broader appetite for obesity-drug deals

Viking Therapeutics stock jumps 11% as CEO flags broader appetite for obesity-drug deals

Viking Therapeutics shares surged about 11% to $34.06 by early afternoon Wednesday amid renewed speculation of a deal in obesity drugs. CEO Brian Lian said more companies are “circling around the space” at the J.P. Morgan healthcare conference. Viking reported Phase 2 trial data for VK2735 showing up to 14.7% weight loss after 13 weeks. No official deals have been announced.
14 January 2026
·
Lumentum stock slides 8% in afternoon trade as tech pulls back; Feb. 3 earnings ahead

Lumentum stock slides 8% in afternoon trade as tech pulls back; Feb. 3 earnings ahead

Lumentum Holdings shares fell 8.1% to $331.93 Wednesday, deepening losses for the Nasdaq-listed optical components maker. The stock swung from an intraday high of $363 to a low of $331.56. Other optics and data-center hardware stocks also declined, including Coherent, Ciena, Arista Networks, and Credo Technology. Lumentum will report fiscal Q2 earnings on Feb. 3 after the market closes.
14 January 2026
···
KLA stock slips despite fresh Wall Street upgrades — here’s what’s driving KLAC now

KLA stock slips despite fresh Wall Street upgrades — here’s what’s driving KLAC now

KLA shares fell 1.7% to $1,417.18 in early afternoon trading Wednesday, tracking a broader decline in chip stocks. The drop came despite new analyst upgrades and price target hikes from Bernstein SocGen, TD Cowen, and Stifel. Peers Applied Materials and Lam Research also slipped. Investors are awaiting KLA’s Jan. 29 earnings and details on 2026 spending plans for advanced chip manufacturing.
14 January 2026
·
SMCI stock slides again as Goldman’s ‘sell’ call puts Super Micro margins back under the microscope

SMCI stock slides again as Goldman’s ‘sell’ call puts Super Micro margins back under the microscope

Super Micro Computer shares fell 1.7% to $28.12 by early afternoon after Goldman Sachs initiated coverage with a “Sell” rating and a $26 price target, citing margin pressure and uncertain profitability. Analyst Katherine Murphy flagged that margins have halved to 9.5% and warned of further downside. Investors are awaiting February results for signs of margin stability. Competitors and rising costs are adding pressure.
14 January 2026
··
Edgewise Therapeutics stock jumps about 11% on 2026 trial calendar — what’s next for EWTX

Edgewise Therapeutics stock jumps about 11% on 2026 trial calendar — what’s next for EWTX

Edgewise Therapeutics shares rose 10.6% to $27.59 by midday Wednesday after the company set timelines for key clinical trial readouts in muscle and heart diseases. Top-line data for Becker muscular dystrophy is expected in Q4 2026, with a U.S. drug application planned for early 2027. Investors are watching for Phase 2 and Phase 1 heart program results in the first half of 2026. Trading volume reached about 1 million shares.
14 January 2026
··
1 … 408 409 410 411 412 … 1,643

Stock Market Today

Go toTop